<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on November 19, 2026 at 4:42 pm by All in One SEO v5.0.5.1 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://ribometrix.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>Ribometrix</title>
		<link><![CDATA[https://ribometrix.com]]></link>
		<description><![CDATA[Ribometrix]]></description>
		<lastBuildDate><![CDATA[Thu, 15 Oct 2026 16:36:52 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://ribometrix.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://ribometrix.com/platform/]]></guid>
			<link><![CDATA[https://ribometrix.com/platform/]]></link>
			<title>Platform</title>
			<pubDate><![CDATA[Thu, 15 Oct 2026 16:36:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/company/team/]]></guid>
			<link><![CDATA[https://ribometrix.com/company/team/]]></link>
			<title>Team</title>
			<pubDate><![CDATA[Mon, 17 Aug 2026 14:40:32 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/careers/]]></guid>
			<link><![CDATA[https://ribometrix.com/careers/]]></link>
			<title>Careers</title>
			<pubDate><![CDATA[Mon, 20 Apr 2026 14:37:08 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/news/]]></guid>
			<link><![CDATA[https://ribometrix.com/news/]]></link>
			<title>News</title>
			<pubDate><![CDATA[Tue, 13 Jan 2026 15:45:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/]]></guid>
			<link><![CDATA[https://ribometrix.com/]]></link>
			<title>Homepage</title>
			<pubDate><![CDATA[Tue, 09 Dec 2025 23:14:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/partnership/]]></guid>
			<link><![CDATA[https://ribometrix.com/partnership/]]></link>
			<title>Partnership</title>
			<pubDate><![CDATA[Mon, 03 Nov 2025 19:32:08 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/contact/]]></guid>
			<link><![CDATA[https://ribometrix.com/contact/]]></link>
			<title>Contact</title>
			<pubDate><![CDATA[Mon, 14 Apr 2025 16:04:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/company/]]></guid>
			<link><![CDATA[https://ribometrix.com/company/]]></link>
			<title>Company</title>
			<pubDate><![CDATA[Fri, 11 Apr 2025 19:28:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/company/history/]]></guid>
			<link><![CDATA[https://ribometrix.com/company/history/]]></link>
			<title>History</title>
			<pubDate><![CDATA[Thu, 10 Apr 2025 21:23:53 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/news/ribometrix-strengthens-leadership-appoints-william-s-marshall-ph-d-as-chief-executive-officer-and-katie-warner-ph-d-as-chief-scientific-officer/]]></guid>
			<link><![CDATA[https://ribometrix.com/news/ribometrix-strengthens-leadership-appoints-william-s-marshall-ph-d-as-chief-executive-officer-and-katie-warner-ph-d-as-chief-scientific-officer/]]></link>
			<title>Ribometrix Strengthens Leadership, Appoints William S. Marshall, Ph.D., as Chief Executive Officer and Katie Warner, Ph.D., as Chief Scientific Officer</title>
			<pubDate><![CDATA[Thu, 09 Jan 2025 14:33:56 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/news/ribometrix-announces-30-million-series-a-funding/]]></guid>
			<link><![CDATA[https://ribometrix.com/news/ribometrix-announces-30-million-series-a-funding/]]></link>
			<title>Ribometrix Announces $30 Million Series A Funding</title>
			<pubDate><![CDATA[Fri, 18 Oct 2024 21:22:03 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/publications/]]></guid>
			<link><![CDATA[https://ribometrix.com/publications/]]></link>
			<title>Publications</title>
			<pubDate><![CDATA[Fri, 18 Oct 2024 21:19:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/news/ribometrix-present-data-supporting-potential-of-eif4e-program-in-kras-mutant-non-small-cell-lung-cancer-at-esmo-2024/]]></guid>
			<link><![CDATA[https://ribometrix.com/news/ribometrix-present-data-supporting-potential-of-eif4e-program-in-kras-mutant-non-small-cell-lung-cancer-at-esmo-2024/]]></link>
			<title>Ribometrix Present Data Supporting Potential of eIF4E Program in KRAS Mutant Non-Small Cell Lung Cancer at ESMO 2024 </title>
			<pubDate><![CDATA[Mon, 16 Sep 2024 12:00:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/publications/eif4e-inhibition-exhibits-anti-tumor-activity-and-re-sensitizes-acquired-resistant-krassupg12c-sup-nsclc-to-kras-inhibitors/]]></guid>
			<link><![CDATA[https://ribometrix.com/publications/eif4e-inhibition-exhibits-anti-tumor-activity-and-re-sensitizes-acquired-resistant-krassupg12c-sup-nsclc-to-kras-inhibitors/]]></link>
			<title>eIF4E inhibition exhibits anti-tumor activity and re-sensitizes acquired resistant KRAS&lt;sup&gt;G12C&lt;/sup&gt; NSCLC to KRAS inhibitors</title>
			<pubDate><![CDATA[Sat, 14 Sep 2024 22:10:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/news/ribometrix-to-present-data-supporting-potential-of-eif4e-program-in-kras-mutant-non-small-cell-lung-cancer-at-esmo-2024/]]></guid>
			<link><![CDATA[https://ribometrix.com/news/ribometrix-to-present-data-supporting-potential-of-eif4e-program-in-kras-mutant-non-small-cell-lung-cancer-at-esmo-2024/]]></link>
			<title>Ribometrix To Present Data Supporting Potential of eIF4E Program in KRAS Mutant Non-Small Cell Lung Cancer at ESMO 2024</title>
			<pubDate><![CDATA[Thu, 05 Sep 2024 12:14:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/publications/2024-aacr-c-myc/]]></guid>
			<link><![CDATA[https://ribometrix.com/publications/2024-aacr-c-myc/]]></link>
			<title>Leveraging an RNA-targeting platform for the discovery of cell-active c-MYC mRNA-binding small molecules</title>
			<pubDate><![CDATA[Mon, 08 Apr 2024 12:46:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/publications/2024-aacr-eif4e/]]></guid>
			<link><![CDATA[https://ribometrix.com/publications/2024-aacr-eif4e/]]></link>
			<title>Development of novel eIF4E inhibitors to potently and selectively suppress tumor growth across multiple indications</title>
			<pubDate><![CDATA[Sun, 07 Apr 2024 20:30:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/news/ribometrix-presents-first-c-myc-data-validating-rna-targeting-platform-and-demonstrates-synergistic-potential-of-eif4e-program-at-aacr-2024/]]></guid>
			<link><![CDATA[https://ribometrix.com/news/ribometrix-presents-first-c-myc-data-validating-rna-targeting-platform-and-demonstrates-synergistic-potential-of-eif4e-program-at-aacr-2024/]]></link>
			<title>Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024 </title>
			<pubDate><![CDATA[Sun, 07 Apr 2024 20:28:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/news/ribometrix-to-present-additional-preclinical-data-for-eif4e-program-at-the-san-antonio-breast-cancer-symposium/]]></guid>
			<link><![CDATA[https://ribometrix.com/news/ribometrix-to-present-additional-preclinical-data-for-eif4e-program-at-the-san-antonio-breast-cancer-symposium/]]></link>
			<title>Ribometrix to Present Additional Preclinical Data for eIF4E Program at the San Antonio Breast Cancer Symposium </title>
			<pubDate><![CDATA[Fri, 08 Dec 2023 20:22:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/publications/2023-sabcs/]]></guid>
			<link><![CDATA[https://ribometrix.com/publications/2023-sabcs/]]></link>
			<title>Pharmacological eIF4E inhibition drives anti-tumor activity in ER+ breast cancer</title>
			<pubDate><![CDATA[Fri, 08 Dec 2023 20:18:50 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/news/ribometrix-demonstrates-rapid-progress-for-eif4e-program-at-san-antonio-breast-cancer-symposium/]]></guid>
			<link><![CDATA[https://ribometrix.com/news/ribometrix-demonstrates-rapid-progress-for-eif4e-program-at-san-antonio-breast-cancer-symposium/]]></link>
			<title>Ribometrix Demonstrates Rapid Progress for eIF4E Program at San Antonio Breast Cancer Symposium</title>
			<pubDate><![CDATA[Fri, 08 Dec 2023 18:00:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/publications/smr-2023/]]></guid>
			<link><![CDATA[https://ribometrix.com/publications/smr-2023/]]></link>
			<title>EIF4E inhibition drives anti-tumor activity in BRAFV600E melanoma</title>
			<pubDate><![CDATA[Fri, 08 Dec 2023 16:20:09 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/news/ribometrix-announces-lead-program-target-smr/]]></guid>
			<link><![CDATA[https://ribometrix.com/news/ribometrix-announces-lead-program-target-smr/]]></link>
			<title>Ribometrix Announces Lead Program Target and Presentation of Preclinical Data at the International Congress of the Society for Melanoma Research</title>
			<pubDate><![CDATA[Mon, 06 Nov 2023 13:49:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/news/small-molecules-against-rna/]]></guid>
			<link><![CDATA[https://ribometrix.com/news/small-molecules-against-rna/]]></link>
			<title>Small Molecules Against RNA</title>
			<pubDate><![CDATA[Thu, 17 Aug 2023 21:08:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/news/matt-smola-to-speak-at-rna-assay-development-screening-summit/]]></guid>
			<link><![CDATA[https://ribometrix.com/news/matt-smola-to-speak-at-rna-assay-development-screening-summit/]]></link>
			<title>Matt Smola to Speak at RNA Assay Development &#038; Screening Summit</title>
			<pubDate><![CDATA[Mon, 31 Jul 2023 16:49:46 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/news/2021-life-sciences-award/]]></guid>
			<link><![CDATA[https://ribometrix.com/news/2021-life-sciences-award/]]></link>
			<title>2021 Life Sciences Award</title>
			<pubDate><![CDATA[Wed, 28 Jun 2023 14:10:02 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/news/ribometrix-announces-collaboration-with-genentech-to-discover-and-develop-rna-targeted-small-molecule-therapeutics/]]></guid>
			<link><![CDATA[https://ribometrix.com/news/ribometrix-announces-collaboration-with-genentech-to-discover-and-develop-rna-targeted-small-molecule-therapeutics/]]></link>
			<title>Ribometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics</title>
			<pubDate><![CDATA[Wed, 28 Jun 2023 14:07:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/news/ribometrix-further-expands-leadership-with-appointment-of-barclay-buck-phillips-as-chief-operating-officer-and-chief-financial-officer/]]></guid>
			<link><![CDATA[https://ribometrix.com/news/ribometrix-further-expands-leadership-with-appointment-of-barclay-buck-phillips-as-chief-operating-officer-and-chief-financial-officer/]]></link>
			<title>Ribometrix Further Expands Leadership with Appointment of Barclay &#8220;Buck&#8221; Phillips as Chief Operating Officer and Chief Financial Officer</title>
			<pubDate><![CDATA[Wed, 28 Jun 2023 13:28:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/news/ribometrix-announces-7-8-million-in-new-funding-to-advance-rna-targeting-drug-discovery-platform/]]></guid>
			<link><![CDATA[https://ribometrix.com/news/ribometrix-announces-7-8-million-in-new-funding-to-advance-rna-targeting-drug-discovery-platform/]]></link>
			<title>Ribometrix Announces $7.8 Million in New Funding to Advance RNA-Targeting Drug Discovery Platform</title>
			<pubDate><![CDATA[Wed, 28 Jun 2023 13:26:22 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/news/ribometrix-raises-7-5-million/]]></guid>
			<link><![CDATA[https://ribometrix.com/news/ribometrix-raises-7-5-million/]]></link>
			<title>Ribometrix Raises $7.5 Million</title>
			<pubDate><![CDATA[Wed, 28 Jun 2023 13:20:07 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://ribometrix.com/news/vertex-and-ribometrix-establish-strategic-collaboration-to-discover-and-develop-rna-targeted-small-molecule-therapeutics/]]></guid>
			<link><![CDATA[https://ribometrix.com/news/vertex-and-ribometrix-establish-strategic-collaboration-to-discover-and-develop-rna-targeted-small-molecule-therapeutics/]]></link>
			<title>Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics</title>
			<pubDate><![CDATA[Fri, 23 Jun 2023 14:29:52 +0000]]></pubDate>
		</item>
				</channel>
</rss>
